Last reviewed · How we verify
A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer
The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
Details
| Lead sponsor | Millennium Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 56 |
| Start date | 2007-08 |
| Completion | 2011-06 |
Conditions
- Cancer
Interventions
- TAK-285 Dose Escalation Cohorts
- TAK-285 Recommended Phase 2 Dosing Cohort
Primary outcomes
- Safety profile, including dose-limiting toxicities, maximum tolerated dose, recommended Phase II dose; and the pharmacokinetic profile. — Duration of study
Countries
United States